ITPRIPL1 binds CD3ε to impede T cell activation and enable tumor immune evasion
暂无分享,去创建一个
J. Brosseau | Huanbin Wang | Lu Xie | Yuan Fang | Shouyan Deng | Wenhua Liang | Zan Shen | Shuhang Wang | Ning Li | Jiawei Shi | Yufan Sun | Yingfei Quan | Yonggang Wang | Jie Xu | Yibo Zhang | Yiting Wang | Jiayang Liu | Hao Chi | Rui Ye | Lishen Shan | Feng Wang | Grace Liu
[1] A. Welm,et al. Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies. , 2024, Cancer cell.
[2] M. Hashimoto,et al. Harnessing CD8 T cell responses using PD-1-IL-2 combination therapy. , 2023, Trends in cancer.
[3] A. Copik,et al. Knockout of the inhibitory receptor TIGIT enhances the antitumor response of ex vivo expanded NK cells and prevents fratricide with therapeutic Fc-active TIGIT antibodies , 2023, Journal for ImmunoTherapy of Cancer.
[4] E. Wherry,et al. CD8+ T cells in the cancer-immunity cycle. , 2023, Immunity.
[5] Hong Zhang,et al. A membrane-associated MHC-I inhibitory axis for cancer immune evasion , 2023, Cell.
[6] C. Fegan,et al. Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy , 2023, Cell.
[7] J. C. Love,et al. Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity , 2023, Cell.
[8] T. Rispens,et al. The unique properties of IgG4 and its roles in health and disease , 2023, Nature Reviews Immunology.
[9] Catherine J. Wu,et al. Dynamics and specificities of T cells in cancer immunotherapy , 2023, Nature Reviews Cancer.
[10] P. Sharma,et al. Immune checkpoint therapy—current perspectives and future directions , 2023, Cell.
[11] Stacy L. Gelhaus,et al. Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment , 2023, Cell.
[12] B. Monk,et al. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. , 2023, The New England journal of medicine.
[13] Mingyao Liu,et al. Enhancing the antitumor immunity of T cells by engineering the lipid-regulatory site of the TCR/CD3 complex. , 2022, Cancer immunology research.
[14] B. Neel,et al. Creating MHC-Restricted Neoantigens with Covalent Inhibitors That Can Be Targeted by Immune Therapy , 2022, Cancer discovery.
[15] Zhonghui Tang,et al. The primordial differentiation of tumor-specific memory CD8+ T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes , 2022, Cell.
[16] B. Malissen,et al. Kinetic proofreading through the multi-step activation of the ZAP70 kinase underlies early T cell ligand discrimination , 2022, Nature Immunology.
[17] G. Hummer,et al. Structure of a fully assembled tumor-specific T cell receptor ligated by pMHC , 2022, Cell.
[18] M. Gonen,et al. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. , 2022, The New England journal of medicine.
[19] L. Gao,et al. PD‐1 mediates decidual γδ T cells cytotoxicity during recurrent pregnancy loss , 2022, American journal of reproductive immunology.
[20] A. Utsunomiya,et al. Identification and characterization of a novel enhancer in the HTLV-1 proviral genome , 2022, Nature Communications.
[21] David R. Liu,et al. Prioritization of autoimmune disease-associated genetic variants that perturb regulatory element activity in T cells , 2022, Nature Genetics.
[22] R. Germain,et al. Tuning T cell receptor sensitivity through catch bond engineering , 2022, Science.
[23] Thomas D. Wu,et al. Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses , 2022, Immunity.
[24] Paul J. Hoffman,et al. Dictionary learning for integrative, multimodal and scalable single-cell analysis , 2022, bioRxiv.
[25] B. Helmink,et al. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade , 2022, Cell.
[26] Xueda Hu,et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells , 2021, Science.
[27] M. Ogris,et al. CD47-targeted cancer immunogene therapy: Secreted SIRPα-Fc fusion protein eradicates tumors by macrophage and NK cell activation , 2021, Molecular therapy oncolytics.
[28] Junzhi Wang,et al. Development of a novel reporter gene assay to evaluate antibody-dependent cellular phagocytosis for anti-CD20 therapeutic antibodies. , 2021, International immunopharmacology.
[29] Junzhi Wang,et al. A reporter gene assay for determining the biological activity of therapeutic antibodies targeting TIGIT , 2021, Acta pharmaceutica Sinica. B.
[30] G. Long,et al. Immune checkpoint inhibitors in melanoma , 2021, The Lancet.
[31] J. Clohessy,et al. Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy , 2021, Cell.
[32] G. Eberl,et al. Dysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer , 2021, Cell.
[33] A. Horuzsko,et al. Humanized Mouse Model as a Novel Approach in the Assessment of Human Allogeneic Responses in Organ Transplantation , 2021, Frontiers in Immunology.
[34] K. Gaus,et al. Canonical T cell receptor docking on peptide–MHC is essential for T cell signaling , 2021, Science.
[35] H. Tien,et al. Distinct clinical and biological characteristics of acute myeloid leukemia with higher expression of long noncoding RNA KIAA0125 , 2020, Annals of Hematology.
[36] Catherine C L Wong,et al. Multiple Signaling Roles of CD3ε and Its Application in CAR-T Cell Therapy , 2020, Cell.
[37] S. Günther,et al. Noncanonical binding of Lck to CD3ε promotes TCR signaling and CAR function , 2020, Nature Immunology.
[38] T. Harrer,et al. Human Fcγ-receptor IIb modulates pathogen-specific versus self-reactive antibody responses in lyme arthritis , 2020, eLife.
[39] D. Longo,et al. Minimal PD-1 expression in mouse and human NK cells under diverse conditions. , 2020, The Journal of clinical investigation.
[40] Peng Jiang,et al. Large-scale public data reuse to model immunotherapy response and resistance , 2020, Genome Medicine.
[41] Shujie Liao,et al. PDL1 blockage increases fetal resorption and Tfr cells but does not affect Tfh/Tfr ratio and B-cell maturation during allogeneic pregnancy , 2020, Cell Death & Disease.
[42] D. Schadendorf,et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma , 2020, Nature.
[43] Hong-Fu Xie,et al. Etanercept biosimilar (recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein) and methotrexate combination therapy in Chinese patients with moderate-to-severe plaque psoriasis: a multicentre, randomized, double-blind, placebo-controlled trial , 2019, Archives of Dermatological Research.
[44] G. Freeman,et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response , 2018, Nature Medicine.
[45] W. Schamel,et al. Anti-CD3 Fab Fragments Enhance Tumor Killing by Human γδ T Cells Independent of Nck Recruitment to the γδ T Cell Antigen Receptor , 2018, Front. Immunol..
[46] T. Chan,et al. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab , 2017, Cell.
[47] T. Graeber,et al. Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells , 2016, Cancer Immunology Research.
[48] J. Sosman,et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2016, Cell.
[49] A. Gingras,et al. Combinatorial proteomic analysis of intercellular signaling applied to the CD28 T-cell costimulatory receptor , 2015, Proceedings of the National Academy of Sciences.
[50] J. Liu,et al. Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity , 2014, Proceedings of the National Academy of Sciences.
[51] M. Wunderlich,et al. OKT3 prevents xenogeneic GVHD and allows reliable xenograft initiation from unfractionated human hematopoietic tissues. , 2014, Blood.
[52] A. Palucka,et al. Development and function of human innate immune cells in a humanized mouse model , 2014, Nature Biotechnology.
[53] A. Órfão,et al. Relevance of Nck–CD3ε Interaction for T Cell Activation In Vivo , 2014, The Journal of Immunology.
[54] O. Boyman,et al. Human natural killer cells prevent infectious mononucleosis features by targeting lytic Epstein-Barr virus infection. , 2013, Cell reports.
[55] C. Benoist,et al. Differential Response of Regulatory and Conventional CD4+ Lymphocytes to CD3 Engagement: Clues to a Possible Mechanism of Anti-CD3 Action? , 2013, The Journal of Immunology.
[56] Mark M. Davis,et al. Distinct T cell receptor signaling pathways drive proliferation and cytokine production in T cells , 2013, Nature Immunology.
[57] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[58] K. Coombes,et al. Robust Gene Expression Signature from Formalin-Fixed Paraffin-Embedded Samples Predicts Prognosis of Non–Small-Cell Lung Cancer Patients , 2011, Clinical Cancer Research.
[59] Anne-Marie Cleton-Jansen,et al. Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating Agents , 2011, Clinical Cancer Research.
[60] R Eils,et al. Comparison of performance of one-color and two-color gene-expression analyses in predicting clinical endpoints of neuroblastoma patients , 2010, The Pharmacogenomics Journal.
[61] M. Friedrich,et al. T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells , 2010, Proceedings of the National Academy of Sciences.
[62] J. Daily,et al. Trypanosoma cruzi Triggers an Early Type I IFN Response In Vivo at the Site of Intradermal Infection1 , 2009, The Journal of Immunology.
[63] L. Staudt,et al. Stromal gene signatures in large-B-cell lymphomas. , 2008, The New England journal of medicine.
[64] E. Reinherz,et al. Structural and functional evidence that Nck interaction with CD3epsilon regulates T-cell receptor activity. , 2008, Journal of molecular biology.
[65] G. Freeman,et al. PD-1 and its ligands in tolerance and immunity. , 2008, Annual review of immunology.
[66] R. Wagner,et al. Reciprocal Regulation of SH3 and SH2 Domain Binding via Tyrosine Phosphorylation of a Common Site in CD3ε1 , 2007, The Journal of Immunology.
[67] J. Mesirov,et al. From the Cover: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005 .
[68] S. Harrison,et al. Crystal structure of a human CD3-ε/δ dimer in complex with a UCHT1 single-chain antibody fragment , 2004 .
[69] A. Weiss,et al. Jurkat T cells and development of the T-cell receptor signalling paradigm , 2004, Nature Reviews Immunology.
[70] Balbino Alarcón,et al. Recruitment of Nck by CD3ϵ Reveals a Ligand-Induced Conformational Change Essential for T Cell Receptor Signaling and Synapse Formation , 2002, Cell.
[71] G. Aversa,et al. INDUCTION OF LONG‐TERM SPECIFIC TOLERANCE TO ALLOGRAFTS IN RATS BY THERAPY WITH AN ANTI‐CD3-LIKE MONOCLONAL ANTIBODY , 1993, Transplantation.
[72] P. Beverley,et al. Human T lymphocyte activation by monoclonal antibodies; OKT3, but not UCHT1, triggers mitogenesis via an interleukin 2-dependent mechanism. , 1984, Journal of immunology.
[73] OUP accepted manuscript , 2021, Nucleic Acids Research.
[74] Z. Guo,et al. T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.
[75] R. N. Brogden,et al. Muromonab CD3 , 2012, Drugs.